Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pemetrexed

Pemetrexed Am J Cancer 2003; 2 (5): 371-372 GUEST COMMENTARIES 1175-6357/03/0005-0371/$30.00/0 © Adis Data Information BV 2003. All rights reserved. combination with carboplatin. A logical step for a registration study was therefore a large randomized clinical trial in combina- A Viewpoint by Pieter E. Postmus tion with a platinum analog versus a platinum analog alone. One Vrije Universiteit Medical Centre, Amsterdam, The might question the value of using a platinum analog as the Netherlands ‘standard’ treatment in the comparator arm of the MPM trial, but Pemetrexed (initially called ‘multi-targeted antifolate’) is a new better chemotherapeutic options are not available, and therefore a drug affecting pyrimidine and purine nucleotide synthesis, which single-agent platinum analog (in this case, cisplatin) was consid- has been evaluated in two large phase III studies. In the initial ered an acceptable comparator. phase I and phase II studies, pemetrexed demonstrated promising The completed phase III trial in patients with MPM demonstra- activity against tumors without a known effective treatment, espe- ted the superiority of the combination of cisplatin with pemetrexed cially relapsed non-small-cell lung cancer and malignant pleural compared with cisplatin monotherapy. Survival time, progression mesothelioma (MPM). Furthermore, pemetrexed could be easily free survival, and response rates http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Pemetrexed

Abstract

Am J Cancer 2003; 2 (5): 371-372 GUEST COMMENTARIES 1175-6357/03/0005-0371/$30.00/0 © Adis Data Information BV 2003. All rights reserved. combination with carboplatin. A logical step for a registration study was therefore a large randomized clinical trial in combina- A Viewpoint by Pieter E. Postmus tion with a platinum analog versus a platinum analog alone. One Vrije Universiteit Medical Centre, Amsterdam, The might question the value of using a platinum analog as the Netherlands...
Loading next page...
 
/lp/springer-journals/pemetrexed-TfZzsOkEyA
Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302050-00012
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2003; 2 (5): 371-372 GUEST COMMENTARIES 1175-6357/03/0005-0371/$30.00/0 © Adis Data Information BV 2003. All rights reserved. combination with carboplatin. A logical step for a registration study was therefore a large randomized clinical trial in combina- A Viewpoint by Pieter E. Postmus tion with a platinum analog versus a platinum analog alone. One Vrije Universiteit Medical Centre, Amsterdam, The might question the value of using a platinum analog as the Netherlands ‘standard’ treatment in the comparator arm of the MPM trial, but Pemetrexed (initially called ‘multi-targeted antifolate’) is a new better chemotherapeutic options are not available, and therefore a drug affecting pyrimidine and purine nucleotide synthesis, which single-agent platinum analog (in this case, cisplatin) was consid- has been evaluated in two large phase III studies. In the initial ered an acceptable comparator. phase I and phase II studies, pemetrexed demonstrated promising The completed phase III trial in patients with MPM demonstra- activity against tumors without a known effective treatment, espe- ted the superiority of the combination of cisplatin with pemetrexed cially relapsed non-small-cell lung cancer and malignant pleural compared with cisplatin monotherapy. Survival time, progression mesothelioma (MPM). Furthermore, pemetrexed could be easily free survival, and response rates

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.